To compare the efficacy and safety of pegylated G-CSF versus non-pegylated G-CSF for patients after HSCT.
This is a protocol.
Pegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for patients after hematopoietic stem cell transplantation
You may also be interested in:
- Prophylactic administration of colony-stimulating factors reduces hospital stay and risk of infections in children with acute lymphoblastic leukaemia
- Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation
- Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation
- Adding plerixafor to G-CSF for stem cell mobilisation for autologous transplantation in people with certain cancers of the blood
- The use of colony-stimulating factors in the supportive care of patients with acute myelogenous leukemia (AML)